Systemic Treatments Options for Hepatocellular Carcinoma

Jennifer L. Wild, BSN RN & R. Kate Kelley, MD
UCSF

This presentation is an excerpt from the ALF 2021 Poster Competition. This competition showcases posters and a brief video created by early career investigators from across the country on six areas of educational focus: fatty liver disease, liver cancer, liver transplantation, pediatric liver disease, rare liver disease and viral hepatitis. Participants are tasked with translating complicated medical information into a poster which can be easily understood by patients or the public. Posters are reviewed by a formal panel of judges comprised of Medical Advisory Council members, Board Members and friends of ALF to select a winner in each category.

In the past 5 years, there have been exciting new advancements in systemic treatment options for primary liver cancer. For nearly a decade, sorafenib was the best 1st line option, with no other treatment options offering better outcomes, but this changed last year with the advent of combination therapy with atezolizumab and bevacizumab. The combination was FDA approved in summer of 2020 and has since been incorporated into treatment guidelines from the American Society of Clinical Oncology and the National Comprehensive Cancer Network. This poster describes the basics of systemic treatments for liver cancer incorporating this update.